Journal ArticleDOI
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Mengyu Feng,Guangbing Xiong,Guangbing Xiong,Zhe Cao,Gang Yang,Suli Zheng,Xujun Song,Lei You,Lianfang Zheng,Taiping Zhang,Taiping Zhang,Yupei Zhao +11 more
Reads0
Chats0
TLDR
In this review, the development and limitations of anti-PD-1/PD-L1 monotherapy in pancreatic cancer are discussed, the underlying mechanism is considered, combination strategies overcoming resistance to anti- PD-1 /PD- L1 immunotherapy, and the prospect of targeting PD- 1/PD/L1 for the immunotherapy of pancreatic cancers is considered.About:
This article is published in Cancer Letters.The article was published on 2017-10-28. It has received 222 citations till now. The article focuses on the topics: Pancreatic cancer & Immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Tumor microenvironment participates in metastasis of pancreatic cancer
TL;DR: This review discusses how the pancreatic cancer microenvironment participates in metastasis, representing a potential target for combination therapy to enhance overall survival.
Journal ArticleDOI
Recent Advances in Hyperthermia Therapy-Based Synergistic Immunotherapy.
TL;DR: The synergistic mechanism of HTT in immunotherapy, including immunogenic cell death and reversal of the immunosuppressive tumor microenvironment is discussed, and these strategies could achieve synergistically enhanced therapeutic outcomes against both primary tumors and metastatic lesions, prevent cancer recurrence, and prolong the survival period.
Journal ArticleDOI
Metabolism of pancreatic cancer: paving the way to better anticancer strategies.
Cheng Qin,Gang Yang,Jinshou Yang,Bo Ren,Huanyu Wang,Guangyu Chen,Fangyu Zhao,Lei You,Weibin Wang,Yupei Zhao +9 more
TL;DR: Investigations of metabolism not only benefit the understanding of carcinogenesis and cancer progression but also provide new insights for treatments against pancreatic cancer.
Journal ArticleDOI
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Zebin Wang,Kaiming Sun,Yonghong Xiao,Bin Feng,Keith Mikule,Xiao Yan Ma,Ningping Feng,Christopher P. Vellano,Lorenzo Federico,Joseph R. Marszalek,Gordon B. Mills,Jeffrey Hanke,Sridhar Ramaswamy,Jing Wang +13 more
TL;DR: Results indicate that niraparib treatment increases the activity of the type I (alpha) and type II (gamma) interferon pathways and enhances the infiltration of CD8+ cells and CD4+ cells in tumors, and uncovered immunomodulatory effects of nirparib that may sensitize tumors to immune checkpoint blockade therapies.
Journal ArticleDOI
Targeting hypoxic tumor microenvironment in pancreatic cancer.
Jinxin Tao,Gang Yang,Wenchuan Zhou,Jiangdong Qiu,Guangyu Chen,Wenhao Luo,Fangyu Zhao,Lei You,Lianfang Zheng,Taiping Zhang,Taiping Zhang,Yupei Zhao +11 more
TL;DR: In this paper, the authors discuss the molecular mechanisms underlying hypoxia-induced aggressive and therapeutically resistant phenotypes in both pancreatic cancerous and stromal cells and focus on innovative therapies targeting the tumor hypoxic microenvironment itself, which hold great potential to overcome the resistance to chemotherapy and radiotherapy and to enhance antitumor efficacy and reduce toxicity to normal tissues.
References
More filters
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
Cancer statistics, 2016
TL;DR: Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.
Journal ArticleDOI
Cancer statistics in China, 2015
Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He +8 more
TL;DR: Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Related Papers (5)
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more